SCHEMBL7149150

SCHEMBL7149150

Nc1nc(SCc2ccccc2)c(Br)c(-c2ccco2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.53
MAPT P10636 4/20 0.53
ALDH1A1 P00352 4/20 0.53
ALOX15 P16050 4/20 0.53
KDM4E B2RXH2 3/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
HSD17B10 Q99714 3/20 0.53
USP2 O75604 2/20 0.53
HTT P42858 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAPK1 P28482 2/20 0.53
CASP7 P55210 2/20 0.53
POLB P06746 2/20 0.53
THRB P10828 1/20 0.53
NR4A1 P22736 1/20 0.53
PTPN7 P35236 1/20 0.53
RECQL P46063 1/20 0.53
DUSP3 P51452 1/20 0.53
BLM P54132 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036818 0.89 ADORA2A (0.49) HPGDMAPTALDH1A1ALOX15KDM4E
SCHEMBL5036755 0.85 ALDH1A1 (0.54) HPGDMAPTALDH1A1ALOX15KDM4E
SCHEMBL7151572 0.83 KDM4E (0.48) HPGDMAPTALDH1A1ALOX15KDM4E
SCHEMBL5041333 0.82 MEN1 (0.69) HPGDMAPTALDH1A1ALOX15KDM4E
SCHEMBL7147771 0.81 ADORA2A (0.52) HPGDMAPTALDH1A1ALOX15KDM4E
SCHEMBL7149959 0.80 ADORA2A (0.54) HPGDMAPTALDH1A1ALOX15KDM4E
SCHEMBL7152501 0.79 ADORA2A (0.43) HPGDMAPTALDH1A1ALOX15KDM4E
SCHEMBL7141937 0.79 ADORA2A (0.50) HPGDMAPTALDH1A1ALOX15KDM4E
SCHEMBL1553903 0.78 ADORA2A (0.60) HPGDMAPTALDH1A1ALOX15KDM4E
Ammonia Solution, Strong SCHEMBL7146156 0.77 ADORA2A (0.55) ADORA2AMPOADORA1ADORA3ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 HPGD 915/4885MAPT 1878/4885ALDH1A1 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.